OncoMatch

OncoMatch/Clinical Trials/NCT04973306

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Is NCT04973306 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Tislelizumab for esophageal squamous cell carcinoma stage ii.

Phase 2/3RecruitingShanghai Zhongshan HospitalNCT04973306Data as of Jun 2026Location: China

Treatment: TislelizumabThe purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) patient.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Tislelizumab

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage II, III

Excluded: Stage CM+, CN3, CT4B, CTIS-1A, CT1BN0

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiotherapy

Cannot have received: targeted therapy

Cannot have received: immunotherapy

Lab requirements

Blood counts

white blood cells >4x10^9 /l; neutrophil >2.0×10^9 /l; hemoglobin > 90 g/l; platelets>100x10^9 /l

Kidney function

glomerular filtration rate (ccr) >60 ml/min; serum creatinine (scr) ≤120 µmol/l

Liver function

total bilirubin <1.5x uln; ast and alt <1.5x uln

Cardiac function

all patients should perform ecg, and those with a cardiac history or ecg abnormality should perform echocardiography with the left ventricular ejection fraction > 50 %

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04973306 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage II or III is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify